Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Roivant executives believe that mosliciguat, administered once per day using a dry powder inhaler, will help fill "an unmet ...

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate ...

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bluebird Bio (BLUE – Research Report), ...

Roivant (ROIV) announces Pulmovant, a new Vant member to develop lung disorder therapy mosliciguat, in licensed from Bayer ...